AstraZeneca says it will build cell therapy base, innovation centre in Shanghai

AstraZeneca will build a cell therapy manufacturing and supply base and innovation centre in Shanghai, aiming to become the first global drugmaker with end-to-end cell therapy capabilities in China. The move vertically integrates manufacturing and R&D in a strategic emerging market, likely accelerating commercialization of cell therapies in China and supporting modest upside to AstraZeneca's pipeline value and local sales.

Analysis

AstraZeneca will build a cell therapy manufacturing and supply base and innovation centre in Shanghai, aiming to become the first global drugmaker with end-to-end cell therapy capabilities in China. The move vertically integrates manufacturing and R&D in a strategic emerging market, likely accelerating commercialization of cell therapies in China and supporting modest upside to AstraZeneca's pipeline value and local sales.